Stefan D. Anker is a German cariologist who is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany.

[1] Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany.

[3] Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993)[1] and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998.

[4] His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy[5] in CHF, ageing, sarcopenia and cancer.

[19][20] Anker has participated in and chaired several consensus meeting and guidelines committees: Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF,[34] TIM-HF,[35] BACH,[36] AUGMENT-HF,[37] ACT-ONE,[38] RESHAPE-HF2,[39] IMPULSE-HF,[40] FAIR-HF2,[41][42] Fair-HFpEF,[42] EMPORER-HFpEF trials[43]).